CRNX

Over the past six months, the FDA approved PALSONIFY in September 2025, leading to a U.S. commercial launch in Q4 2025, generating $5.4 million in net product revenue, and $10.3 million in Q1 2026. Crinetics reported its Q4 2025 financial results on February 26, 2026, after which CRNX shares declined by 6.0%. On May 7, 2026, Crinetics reported Q1 2026 revenue of $10.7 million, exceeding forecasts, and an EPS of -$1.23, surpassing expectations, causing the stock to rise 4.27% in after-hours trading. In March 2026, Crinetics submitted a Marketing Authorization Application for PALSONIFY in Brazil, and the European Commission approved PALSONIFY for acromegaly in adults. Between April 7, 2025, and April 2, 2026, the share price increased by 41.13%. As of May 8, 2026, the stock price was $37.48, representing a 22.16% increase over the past year. In March 2026, the CEO and CFO sold shares at average prices of $37.37 and $39.67, respectively.